常规低剂量氧疗对急性卒中成人死亡和残疾的影响:卒中氧疗研究随机临床试验
这项单盲随机临床试验纳入英国136个中心的8003例急性卒中成人,在入院24小时内随机分为持续氧疗72小时组、夜间氧疗3晚组或对照组。结果显示,氧疗组与对照组在90天死亡和残疾方面无显著差异,未发现获益亚组,不支持在此类患者中预防性使用低剂量氧疗。
要点
- 急性卒中成人预防性低剂量氧疗未降低90天死亡和残疾(OR 0.97,95%CI 0.89-1.05)。
- 持续氧疗与夜间氧疗在90天结局上无显著差异(OR 1.03,95%CI 0.93-1.13)。
- 未发现可从氧疗中获益的亚组,未识别出显著危害。
核心结论
- 在非低氧血症的急性卒中患者中,预防性低剂量氧疗未减少3个月时的死亡或残疾,这些发现不支持在此类情况下使用低剂量氧疗。
研究设计与样本
- 单盲随机临床试验,纳入英国136个参与中心的8003例急性卒中成人,入院24小时内入组,随机比例1:1:1。
- 首例患者入组于2008年4月24日,末次随访于2015年1月27日。
主要发现
- 共纳入8003例患者,其中男性4398例(55%),平均(SD)年龄72(13)岁,美国国立卫生研究院卒中量表评分中位数5分,平均基线氧饱和度96.6%。
- 主要结局在7677例(96%)参与者中可获取;氧疗组 vs 对照组的未校正OR为0.97(95%CI 0.89-1.05;P=0.47),持续氧疗组 vs 夜间氧疗组的OR为1.03(95%CI 0.93-1.13;P=0.61)。
- 未识别出可从氧疗中获益的亚组。
- 至少发生1次严重不良事件:持续氧疗组348例(13.0%),夜间氧疗组294例(11.0%),对照组322例(12.1%);未发现显著危害。
关键数值与推荐
- 主要结局采用改良Rankin量表评分(残疾范围0分[无症状]至6分[死亡];最小临床重要差异1分),在90天时通过邮寄问卷评估(参与者知晓分组,评估者设盲)。
- 改良Rankin量表评分采用序贯逻辑回归分析,得出相邻残疾等级改善(降低)的 common OR;OR大于1.00表示改善。
- 氧疗通过鼻导管给予:基线氧饱和度≤93%时3 L/min,氧饱和度>93%时2 L/min。
临床怎么用
- 原文结论指出,这些发现不支持在非低氧血症的急性卒中患者中使用低剂量氧疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hypoxia is common in the first few days after acute stroke, is frequently intermittent, and is often undetected. Oxygen supplementation could prevent hypoxia and secondary neurological deterioration and thus has the potential to improve recovery. OBJECTIVE: To assess whether routine prophylactic low-dose oxygen therapy was more effective than control oxygen administration in reducing death and disability at 90 days, and if so, whether oxygen given at night only, when hypoxia is most frequent, and oxygen administration is least likely to interfere with rehabilitation, was more effective than continuous supplementation. DESIGN, SETTING, AND PARTICIPANTS: In this single-blind randomized clinical trial, 8003 adults with acute stroke were enrolled from 136 participating centers in the United Kingdom within 24 hours of hospital admission if they had no clear indications for or contraindications to oxygen treatment (first patient enrolled April 24, 2008; last follow-up January 27, 2015). INTERVENTIONS: Participants were randomized 1:1:1 to continuous oxygen for 72 hours (n = 2668), nocturnal oxygen (21:00 to 07:00 hours) for 3 nights (n = 2667), or control (oxygen only if clinically indicated; n = 2668). Oxygen was given via nasal tubes at 3 L/min if baseline oxygen saturation was 93% or less and at 2 L/min if oxygen saturation was greater than 93%. MAIN OUTCOMES AND MEASURES: The primary outcome was reported using the modified Rankin Scale score (disability range, 0 [no symptoms] to 6 [death]; minimum clinically important difference, 1 point), assessed at 90 days by postal questionnaire (participant aware, assessor blinded). The modified Rankin Scale score was analyzed by ordinal logistic regression, which yields a common odds ratio (OR) for a change from one disability level to the next better (lower) level; OR greater than 1.00 indicates improvement. RESULTS: A total of 8003 patients (4398 (55%) men; mean [SD] age, 72 [13] years; median National Institutes of Health Stroke Scale score, 5; mean baseline oxygen saturation, 96.6%) were enrolled. The primary outcome was available for 7677 (96%) participants. The unadjusted OR for a better outcome (calculated via ordinal logistic regression) was 0.97 (95% CI, 0.89 to 1.05; P = .47) for oxygen vs control, and the OR was 1.03 (95% CI, 0.93 to 1.13; P = .61) for continuous vs nocturnal oxygen. No subgroup could be identified that benefited from oxygen. At least 1 serious adverse event occurred in 348 (13.0%) participants in the continuous oxygen group, 294 (11.0%) in the nocturnal group, and 322 (12.1%) in the control group. No significant harms were identified. CONCLUSIONS AND RELEVANCE: Among nonhypoxic patients with acute stroke, the prophylactic use of low-dose oxygen supplementation did not reduce death or disability at 3 months. These findings do not support low-dose oxygen in this setting. TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN52416964.
引用
- Roffe C, Nevatte T, Sim J, et al. Effect of Routine Low-Dose Oxygen Supplementation on Death and Disability in Adults With Acute Stroke: The Stroke Oxygen Study Randomized Clinical Trial. JAMA. 2017. PMID: 28973619. doi:10.1001/jama.2017.11463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。